Invivyd Target of Unusually High Options Trading (NASDAQ:IVVD)

Invivyd, Inc. (NASDAQ:IVVD) was the target of unusually large options trading on Friday. Stock traders acquired 2,953 call options on the stock. This represents an increase of 283% compared to the average daily volume of 771 call options.

Analyst Upgrades and Downgrades

Several research firms have issued reports on IVVD. Cantor Fitzgerald assumed coverage on shares of Invivyd in a research report on Monday, October 6th. They issued an “overweight” rating and a $10.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a report on Friday, October 31st. HC Wainwright raised their price objective on Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, October 31st. D. Boral Capital lifted their target price on Invivyd from $1.00 to $2.00 and gave the company a “buy” rating in a research report on Monday, October 6th. Finally, Zacks Research downgraded Invivyd from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 15th. Four equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $6.39.

Invivyd Price Performance

NASDAQ IVVD traded up $0.83 during midday trading on Friday, hitting $2.60. 89,004,753 shares of the company traded hands, compared to its average volume of 7,593,887. Invivyd has a 52 week low of $0.35 and a 52 week high of $2.74. The company’s 50-day simple moving average is $1.53 and its 200-day simple moving average is $1.04. The company has a market cap of $604.95 million, a PE ratio of -5.31 and a beta of 0.64.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%.The company had revenue of $13.13 million during the quarter, compared to the consensus estimate of $12.00 million. On average, research analysts predict that Invivyd will post -1.64 earnings per share for the current year.

Insider Activity

In other news, insider Jill Andersen sold 49,402 shares of the company’s stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total value of $28,159.14. Following the transaction, the insider directly owned 84,446 shares in the company, valued at approximately $48,134.22. This represents a 36.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 277,654 shares of company stock worth $167,215 over the last ninety days. 25.40% of the stock is currently owned by insiders.

Institutional Trading of Invivyd

Several hedge funds have recently modified their holdings of IVVD. Catalyst Funds Management Pty Ltd purchased a new position in shares of Invivyd in the 2nd quarter worth approximately $27,000. Vanguard Personalized Indexing Management LLC boosted its stake in Invivyd by 238.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock valued at $29,000 after acquiring an additional 28,146 shares in the last quarter. Nuveen LLC purchased a new position in Invivyd in the first quarter worth $65,000. XTX Topco Ltd acquired a new position in shares of Invivyd during the first quarter worth $66,000. Finally, Invesco Ltd. increased its position in shares of Invivyd by 190.6% during the first quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock worth $66,000 after purchasing an additional 71,485 shares in the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.